MicroPort Scientific Corporation
微創醫療科學有限公司*
(Incorporated in the Cayman Islands with limited liability)
(Stock code: 00853)

POSITIVE PROFIT ALERT

This announcement is made by MicroPort Scientific Corporation (the "**Company**", and together with its subsidiaries, the "**Group**") pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Cap.571, Laws of Hong Kong).

The board of directors of the Company (the "**Board**") is pleased to inform holders of the Company's shares and securities and potential investors that, based on a preliminary review of the information currently available to the Board, the Group is expected to record approximately 30% to 35% increase in the profit attributable to equity shareholders of the Company for the year ended 31 December 2017 as compared with that for the year ended 31 December 2016. The significant increase in the unaudited profit attributable to equity shareholders of the Company for the year ended 31 December 2017 is principally attributable to:

(1) a significant growth in revenue from the cardiovascular and endovascular segments in the PRC market, and in particular, a significant revenue growth of our third generation coronary stent product Firehawk™ Drug Eluting Stent; and

(2) a substantial reduction of net loss of the OrthoRecon business due to the improvement in revenue and gross margin.

The Company is still in the process of preparing and completing the annual results of the Group for the year ended 31 December 2017 (the "**2017 Annual Results**"). The information contained in this announcement is a preliminary assessment made by the Board based on the latest management accounts of the Group which have not been audited or reviewed by the independent auditors of the Company. Holders of the Company's shares and securities and potential investors are advised to read the Company's announcement of the 2017 Annual Results carefully, which is expected to be published before the end of March 2018 and the information disclosed in which shall prevail.

Holders of the Company's shares and securities and potential investors are advised to exercise caution when dealing in the shares and securities of the Company.

By Order of the Board
MicroPort Scientific Corporation
Dr. Zhaohua Chang
Chairman

Shanghai, the People's Republic of China, 28 February 2018

As at the date of this announcement, the executive director is Dr. Zhaohua Chang; the non-executive directors are Mr. Norihiro Ashida, Mr. Hiroshi Shirafuji, Ms. Weiwei Chen and Ms. Janine Junyuan Feng; and the independent non-executive directors are Mr. Jonathan H. Chou, Dr. Guoen Liu and Mr. Chunyang Shao.

* *for identification purpose only*